NO942550L - Humanproteaseinhibitorvariant av Kunitz-type - Google Patents

Humanproteaseinhibitorvariant av Kunitz-type

Info

Publication number
NO942550L
NO942550L NO942550A NO942550A NO942550L NO 942550 L NO942550 L NO 942550L NO 942550 A NO942550 A NO 942550A NO 942550 A NO942550 A NO 942550A NO 942550 L NO942550 L NO 942550L
Authority
NO
Norway
Prior art keywords
amino acid
xaa
naturally occurring
occurring amino
image
Prior art date
Application number
NO942550A
Other languages
English (en)
Other versions
NO942550D0 (no
Inventor
Fanny Norris
Kjeld Norris
Soeren Erik Bjoern
Lars Christian Petersen
Ole Hvilsted Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942550D0 publication Critical patent/NO942550D0/no
Publication of NO942550L publication Critical patent/NO942550L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Amplifiers (AREA)

Abstract

Variant av humanprotease- inhibitorområde II av Kunitz-type fra vevsfaktorreaksj onsveiinhibitor (TFPI), hvor varianten omfatter den følgende aminosyresekvens X1 Asp Phe Cys Phe Leu Glu Glu Asp X2 Gly X3 Cys X4 X5 X6 Xr X8 X9 Tyr Phe Tyr Asn Asn Gin Thr Lys Gin Cys Glu Arg Phe X10 Tyr Gly Gly Cys X11 X12 X13 Met Asn Asn Phe Xu Thr Leu Glu Glu Cys Lys Asn Ile Cys Glu Asp X15 (sekvensidentitet nr. 1), hvor X1 er H eller 1-5 naturlig forekommende aminosyrerester bortsett fra Cys, X2-X14 er hver uavhengig av hverandre en naturlig forekommende aminosyrerest, og X15 er OH eller 1-5 naturlig forekommende aminosyrerester bortsett fra Cys, med det forbehold at minst en av aminosyrerestene X1-X15 er forskjellig fra den tilsvarende amino- syrerest i den naturlig forekommende sekvens.
NO942550A 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type NO942550L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK9200001 1992-01-07
PCT/DK1993/000004 WO1993014121A1 (en) 1992-01-07 1993-01-07 A human kunitz-type protease inhibitor variant

Publications (2)

Publication Number Publication Date
NO942550D0 NO942550D0 (no) 1994-07-06
NO942550L true NO942550L (no) 1994-09-07

Family

ID=8153770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942550A NO942550L (no) 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type

Country Status (18)

Country Link
US (1) US5576294A (no)
EP (1) EP0621871B1 (no)
JP (1) JP3350549B2 (no)
KR (1) KR100278036B1 (no)
AT (1) ATE154938T1 (no)
AU (1) AU676145B2 (no)
CA (1) CA2127249A1 (no)
CZ (1) CZ284911B6 (no)
DE (1) DE69311893T2 (no)
ES (1) ES2104121T3 (no)
FI (1) FI943233A (no)
HU (1) HU218104B (no)
IL (1) IL104325A (no)
NO (1) NO942550L (no)
NZ (1) NZ246569A (no)
PL (1) PL175422B1 (no)
WO (1) WO1993014121A1 (no)
ZA (1) ZA9395B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) * 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
DE69533544T2 (de) 1994-01-11 2006-02-23 Dyax Corp., Cambridge Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
EP0774001B1 (en) * 1994-08-05 2002-10-16 Chiron Corporation Production of tissue factor pathway inhibitor
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
YU8997A (sh) * 1996-03-11 1999-09-27 Bayer Corporation Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
CN1229138C (zh) * 1998-12-22 2005-11-30 拜尔公开股份有限公司 加速粘液纤毛的清除速率的方法
GB9916913D0 (en) * 1999-07-19 1999-09-22 Natural Enviromental Research Inhibitor proteins
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
JP2005537006A (ja) 2002-08-28 2005-12-08 ダイアックス、コープ 臓器及び組織の保存方法
ES2362424T3 (es) * 2003-01-07 2011-07-05 Dyax Corporation Biblioteca del dominio kunitz.
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
CA2643693A1 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
SI2379096T1 (sl) 2008-12-19 2020-03-31 Baxalta GmbH Zaviralci TFPI in postopki uporabe
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
CN101798346B (zh) * 2009-02-06 2013-05-29 复旦大学 一种酵母表达的长效重组人组织因子途径抑制物
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
KR101391988B1 (ko) 2011-11-04 2014-05-08 동아대학교 산학협력단 항섬유소용해 기능을 가진 호박벌 독액의 쿠니츠 타입 세린 프로테아제 저해 폴리펩티드 및 이를 코딩하는 염기서열
DK2827883T3 (da) 2012-03-21 2019-07-29 Baxalta GmbH Tfpi-inhibitorer og fremgangsmåder til anvendelse
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
DE69311893T2 (de) 1998-02-05
HU218104B (hu) 2000-06-28
EP0621871B1 (en) 1997-07-02
FI943233A0 (fi) 1994-07-06
NO942550D0 (no) 1994-07-06
WO1993014121A1 (en) 1993-07-22
IL104325A (en) 2000-10-31
CA2127249A1 (en) 1993-07-22
ES2104121T3 (es) 1997-10-01
NZ246569A (en) 1996-05-28
AU3345993A (en) 1993-08-03
AU676145B2 (en) 1997-03-06
ATE154938T1 (de) 1997-07-15
EP0621871A1 (en) 1994-11-02
FI943233A (fi) 1994-07-06
HUT70295A (en) 1995-09-28
ZA9395B (en) 1993-08-20
IL104325A0 (en) 1993-05-13
DE69311893D1 (de) 1997-08-07
CZ284911B6 (cs) 1999-04-14
PL175422B1 (pl) 1998-12-31
HU9401991D0 (en) 1994-09-28
CZ164994A3 (en) 1994-12-15
US5576294A (en) 1996-11-19
JP3350549B2 (ja) 2002-11-25
KR100278036B1 (ko) 2001-01-15
KR940703854A (ko) 1994-12-12
JPH07506335A (ja) 1995-07-13

Similar Documents

Publication Publication Date Title
NO942550D0 (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942551D0 (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942549L (no) Humanproteaseinhibitorvariant av Kunitz-type
FI943235A (fi) Uusi ihmisen Kunitz-tyyppinen proteaasiestäjä ja sen muunnnoksia
ZA923602B (en) Inhibitors of cathepsin g and elastase for preventing connective tissue degradation
CA2043228A1 (en) Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which result from vascular lesions
DE69420145D1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
DE3569541D1 (en) Pharmacologically active peptides
EP1225184A4 (en) HUMAN ANTITHROMBIN VARIANTS
NO901558L (no) Vasoaktive peptider.
SE8901278L (sv) Peptidderivat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application